The Two-Decade Head Start: How the Pouyan Method Anticipated the Psychedelic Medicine Revolution — and What the Science Actually Says

The hypothesis the world’s most conservative institutions are now spending billions to test was formed in 2007 — and has been operating inside a licensed, physician-supervised facility since 2011. Here is the published science behind every component of it, and an honest account of what we do not claim.

A Hypothesis Formed the Hard Way

Every legitimate scientific idea begins with an observation. Johnny Tabaie’s began with two.

The first was personal and searing. His brother died by suicide — not on the street, not abandoned, but inside a licensed, medically supervised rehab facility, after being given a psychiatric medication. The system that was supposed to save him was, in the family’s experience, the system that failed him.

The second observation was his own body. Tabaie was first prescribed psychiatric medication at thirteen years old. What followed was the trajectory that hundreds of thousands of families will recognize: years of escalating prescriptions, dependence, and the discovery — repeated across more than a dozen conventional treatment attempts — that the standard model of care could stabilize him but never seemed to heal him.

He is open about what he is and what he is not. Johnny Tabaie is not a physician, and has never prescribed a medication to any client — every medical procedure at Holistic Sanctuary and Sanctuary Tulum is performed under the supervision of licensed medical staff, led by Medical Director Dr. Jose A. Jimenez, MD. Tabaie’s training came from somewhere else: from surviving the system, from studying what actually pulled him out, and from two decades of systematic observation, application, and elimination — the working method of empirical science, applied one guest at a time.

The hypothesis he formed in 2007 can be stated in one sentence:

If you combine nature-derived medicines with intensive physiological restoration — instead of managing symptoms with pharmaceuticals — the body and brain have a better chance of genuine recovery, without the side-effect burden that pharmaceutical maintenance carries.

In 2007, that idea placed you far outside the mainstream. In 2011, Tabaie launched it anyway — not as an underground retreat, but inside a licensed, medically supervised facility with oceanfront accommodations, licensed nurses and physicians, and formal screening protocols. Fifteen years later, the facility reports more than 5,000 medically supervised plant-medicine ceremonies conducted under that model, representing tens of thousands of hours of hands-on clinical protocol work — and, per the facility’s internal record, zero serious adverse incidents across that entire history.

And in 2026, Eli Lilly wrote a $3.8 billion check that says the core of that 2007 hypothesis was pointed in the right direction all along.

The protocol integrates five sacred plant medicines — ibogaine, ayahuasca, psilocybin, DMT, and 5-MeO-DMT — with an intensive physiological stack: hyperbaric oxygen therapy, NAD+ and proprietary IV formulations, superfood-based nutrition, daily structured cardio, colonics and cellular detoxification, therapeutic massage, Reiki, yoga, and breathwork. Every element is calibrated to the individual after a full medical and psychiatric evaluation.

That is the method. Now for the part that matters most: what does the published science actually say about its components?

Ayahuasca: Rapid Antidepressant Effects in a Placebo-Controlled Trial

Ayahuasca is no longer a matter of anecdote. In a randomized, placebo-controlled trial published in Psychological Medicine, a single ayahuasca session produced rapid, significant antidepressant effects in patients with treatment-resistant depression — effects measurable within days.⁴ Longer-term observational work has found reductions in depressive symptoms sustained at extended follow-up in a majority of participants.

For trauma specifically, the mechanism research is compelling: ayahuasca’s active compound, DMT, acts on the serotonin 2A receptor system implicated in emotional memory processing — the same system through which psilocybin appears to enable trauma reprocessing. Clinical trials for ayahuasca in PTSD specifically remain at an earlier stage, and we describe them that way.

DMT: Significant and Lasting Effects on Depression

In a Phase IIa randomized clinical trial at Imperial College London, intravenous DMT was tested against placebo in patients with depression. The result: significantly greater reductions in depression severity than placebo, with effects persisting up to six months after treatment.⁵ Imperial’s psychedelic research group — one of the two most influential in the world, alongside Johns Hopkins — has also produced the neuroimaging work explaining why: these compounds temporarily quiet the brain’s default mode network, the circuit responsible for rigid, self-referential rumination, opening a window of heightened neuroplasticity in which entrenched patterns become changeable.

Psilocybin: Breakthrough Therapy Designation and Twelve-Month Durability

The psilocybin evidence is the deepest in the field. In a Johns Hopkins trial published in JAMA Psychiatry, adults with major depressive disorder received two psilocybin doses with supportive therapy: 67% showed a greater-than-50% reduction in depression symptoms at one week, and 71% at four weeks.⁶ The twelve-month follow-up, published in 2022, found 75% of participants still responding and 58% in full remission a year after treatment.⁷

The U.S. Food and Drug Administration has granted psilocybin Breakthrough Therapy designation — twice — for both treatment-resistant depression and major depressive disorder. That designation is reserved for therapies that preliminary evidence suggests may be substantially better than existing treatment.

5-MeO-DMT: The Compound Behind the $3.8 Billion Bet

5-MeO-DMT produces the shortest and most intense experience in the psychedelic pharmacopeia — and some of the most striking early data. A Johns Hopkins–affiliated study published in The American Journal of Drug and Alcohol Abuse found that 5-MeO-DMT use in a structured setting was associated with unintended improvements in depression and anxiety in roughly 80% of participants reporting those conditions.⁸ A European study in Psychopharmacology found a single inhalation was related to sustained increases in life satisfaction and mindfulness-related capacities, with reductions in psychopathological symptoms at follow-up.⁹ A formal Phase 1/2 trial of a vaporized 5-MeO-DMT formulation in treatment-resistant depression, published in Frontiers in Psychiatry, established initial safety and efficacy signals¹⁰ — the research lineage that leads directly to BPL-003 and Eli Lilly’s acquisition.

This is the compound Holistic Sanctuary has offered as a single, medically supervised, private ceremony for years — screened, monitored, and integrated into a longer protocol rather than sold as a standalone weekend experience.

The Physiological Foundation: Why the Method Is More Than Ceremonies

Here is the insight that separates the Pouyan Method from every 7-day ibogaine clinic and 3-day mushroom retreat on the market: a powerful ceremony delivered to a depleted, inflamed, nutrient-starved body is a wasted ceremony. The plant medicine opens the neuroplastic window. What the body does inside that window is determined by its physiological condition. That is what the rest of the protocol exists to optimize — and each component has its own published evidence base.

It lengthened telomeres in a prospective human trial. In 2020, researchers at Tel Aviv University published a prospective trial in the journal Aging: sixty daily HBOT sessions in healthy older adults produced a measurable increase in telomere length of over 20% in immune cell populations, alongside a significant reduction in senescent (“aged”) cells.¹² Telomeres — the protective caps on chromosomes that shorten as we age — are among the most studied biomarkers of cellular aging. Does this prove HBOT extends human lifespan? No — and we will not claim it does. Telomere length is a biomarker of aging, not a demonstrated guarantee of longevity, and this was a single trial. But it is a genuine, peer-reviewed finding from a real research group, and it is the scientific basis for HBOT’s growing role in longevity medicine.

It improved fibromyalgia in a randomized trial. A randomized controlled trial published in PLoS ONE found that a course of HBOT produced significant improvement in fibromyalgia symptoms and — remarkably — corresponding changes in brain activity on imaging, suggesting the therapy was rectifying the abnormal brain patterns associated with the condition.¹³

For traumatic brain injury and cognitive decline, the evidence is promising and still maturing. Multiple trials, largely from the same Israeli research group, have reported improved cognitive function and cerebral blood flow in post-stroke, post-concussion, and age-related cognitive decline populations. This research is genuinely encouraging; it is not yet settled consensus, and we describe it as what it is — an active, promising frontier.

Why Duration Matters: Four to Twelve Weeks, Not Seven Days

Walk through the logic of the typical ibogaine clinic: fly in, brief screening, ibogaine on day two or three, recover for a day, fly home. Total exposure: five to seven days. Now hold that against what the science above actually describes.

The neuroplastic window opened by these compounds extends for days to weeks after the experience. The Johns Hopkins psilocybin protocol embedded its doses inside a structured program of preparation and integration — and its twelve-month durability numbers came from that structure, not from the molecule alone. The Stanford ibogaine study’s veterans were assessed across a full month of structured follow-up. Nothing in the published literature suggests that a compound administered to an unprepared body and abandoned after 72 hours produces durable change. Everything in it suggests the opposite: preparation and integration are where the healing consolidates.

That is the entire argument for the four-to-twelve-week model. The first weeks physically prepare the body — tapering medications safely, restoring nutrition, beginning HBOT and IV therapy. The ceremonies are sequenced at the point of maximum readiness. And the weeks after are where integration, continued physiological restoration, and daily one-on-one work turn a profound experience into a changed life. A seven-day detox is not a smaller version of this. It is a different — and, we would argue, inadequate — product entirely.

Experience, Expertise, Authoritativeness, Trust — Measured Honestly

Google formalized a standard for evaluating health content: E-E-A-T — Experience, Expertise, Authoritativeness, Trustworthiness. It is worth applying that standard, honestly, to this organization.

Experience. The founder lived the failure of the conventional system personally — medicated at thirteen, more than a dozen conventional treatment attempts, a brother lost to suicide inside a licensed facility. He then spent fifteen years and a reported 30,000+ hands-on clinical hours building, measuring, and refining the alternative. Firsthand experience is the “E” Google added to its standard in 2022 precisely because it cannot be faked — and this is about as firsthand as experience gets.

Expertise. The clinical expertise is held where it should be: in licensed physicians, nurses, and a Medical Director with three decades of practice and internationally recognized credentials. The protocol expertise — the sequencing, preparation, and integration system refined across 5,000+ supervised ceremonies — is held by its creator. The two work together, and neither pretends to be the other.

Authoritativeness. The method anticipated, by more than a decade, the direction that Johns Hopkins, Imperial College, Stanford, the FDA’s Breakthrough Therapy program, and now Eli Lilly have all since taken. Being early is not the same as being authoritative — but being early and still operating, licensed, fifteen years later, while the mainstream arrives at your thesis, is a form of authority that no press release can manufacture.

Trustworthiness. Trust is earned by what an organization refuses to claim. Which brings us to the most important section of this article.

The Road Ahead

The next few years will bring Phase 3 results for synthetic 5-MeO-DMT, expanding psilocybin trials, and — if the current trajectory holds — the formal medicalization of compounds that were dismissed as fringe when Johnny Tabaie built a protocol around them in a licensed oceanfront facility in 2011.

When that happens, the pharmaceutical industry will sell the molecule. What it will not sell is the fifteen years of protocol experience, the preparation and integration architecture, the one-to-one model, the physiological restoration stack, and the safety record built around those molecules — one guest at a time, without a single corner cut.

That is the Pouyan Method. That is Holistic Sanctuary. And now the world is catching up.